SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.

ABSTRACT:

Objective

To analyse the safety, immunogenicity and factors affecting antibody response to Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) vaccination in patients with SSc.

Methods

This is a phase 4 prospective study within a larger trial of two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in 51 SSc patients compared with 153 controls. Anti-SARS-CoV-2-IgG and neutralizing antibodies (NAb) were assessed at each vaccine shot (D0/D28) and 6 weeks after the second dose(D69), only in individuals with negative baseline IgG/NAb and those who did not have coronavirus-19(COVID19) during follow-up. Vaccine safety was also assessed in all participants.

Results

Patients and controls had comparable median ages [48(38.5-57) vs 48(38-57) years, P =0.945]. Patient

SUBMITTER: Sampaio-Barros PD 

PROVIDER: S-EPMC8689834 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature